Colleagues engaging in discussion

Events

First India AstraZeneca/Nobel Medicines Initiative Event Inspires

In March AstraZeneca and Nobel Media brought 1996 Nobel Laureate in Physiology, or Medicine Professor Peter Charles Doherty to the Indian Institute of Science (IISc) in Bangalore.

“As AstraZeneca is an innovation-driven company, I think it is excellent that we can provide such a unique opportunity for people to interact with Nobel laureates like Professor Doherty and learn directly about world renowned scientific work,”

Dr Steve Yang, VP Asia and Emerging Markets R&D.

Read article

Previous events

AstraZeneca Showcases New Integrated Externalisation Model at US R&D and VC days

AstraZeneca Showcases New Integrated Externalisation Model

Boston, Massachusetts

Senior R&D and Business Development leaders from across AstraZeneca and MedImmune teamed up in Boston, Massachusetts to engage in discussions with representatives from academia, biotech and venture capital (VC) funds about the critical role that access to external scientific innovation plays in delivering new and valued medicines to all stakeholders including payers, investors and, most importantly, patients.

Our goal is to become fully immersed in the entire partnering ecosystem in order to enable us to be front of mind for potential opportunities as well as to stand out from the competition as the partner of choice. Currently six of our nine of Phase III products are the result of successful partnerships and we are committed to successfully commercialising innovation in healthcare whether it is derived from internal or external sources.

Shaun Grady, VP Strategic Partnering & Business Development

Read more

BioPartnering Europe 2011

BioPartnering Europe 2011

October 9 - 11

London, United Kingdom

AstraZeneca had a high profile at a recent business partnering event in Europe – sowing the seeds for future deals and supporting our externalisation efforts going forward.

Read more about the event

European VC Day

June 2011

London, United Kingdom

AstraZeneca kicked off our Partnership Campaign at the European Venture Capital Day at the London Stock Exchange.

Read more about the event

2011 BIO International Convention

BIO International 2011

June 27 - 30

Washington D.C, United States

BIO International is widely recognised as the world’s best ‘one-stop shop’ for fostering new business partnerships. This year AstraZeneca took every opportunity to demonstrate its drive to be a world leader in collaborating with the best life sciences companies.

Read more about the event

ChinaBIO

May 11 - 12

Beijing, China

The recent ChinaBio Partnering Forum in Shanghai, China saw Dr Steve Yang, AstraZeneca’s Head of R&D, Asia & Emerging Markets participate in the plenary discussion at the two-day meeting along with other senior industry R&D leaders.

Read more

World Health Day

April 7

David Brennan, AstraZeneca Chief Executive Officer, speaking about World Health Day and antimicrobial resistance (AMR) at an International Federation of Pharmaceutical Manufacturers (IFPMA) conference.

Read more

Innovation in Russian healthcare

February 22

Moscow, Russia

The international “Innovation in Russian Healthcare” conference in Moscow on 22 February 2010 made an important contribution to the discussion of how to bridge the gap between developments in fundamental science and commercial success in the pharmaceutical and healthcare market.

Read more

Dr Bob Holland presents at BioPartnering Europe

Dr Bob Holland presents at BioPartnering Europe

Dr Bob Holland presents at BioPartnering Europe

Dr Bob Holland, AstraZeneca VP Personalised Healthcare and Biomarker Support, talks about our Personalised Healthcare strategy and how it has partnering absolutely at the heart of the way that we’re approaching the creation of new stratified medicines.

Watch the video

Dr Bob Holland, AstraZeneca VP Personalised Healthcare and Biomarker Support, talks about our Personalised Healthcare strategy and how it has partnering absolutely at the heart of the way that we’re approaching the creation of new stratified medicines.